Related references
Note: Only part of the references are listed.Life after transplant: are we becoming high maintenance in AML?
A. M. Brunner et al.
BONE MARROW TRANSPLANTATION (2016)
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
Enrique M. Ocio et al.
HAEMATOLOGICA (2015)
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M. Devine et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study
Enrique M. Ocio et al.
HAEMATOLOGICA (2015)
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Jan M. Middeke et al.
BLOOD (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Jesus F. San-Miguel et al.
LANCET ONCOLOGY (2014)
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial
Sung Won Choi et al.
LANCET ONCOLOGY (2014)
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
Daniel J. DeAngelo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
D. J. DeAngelo et al.
LEUKEMIA (2013)
HDAC inhibitor therapy in autoimmunity and transplantation
Wayne W. Hancock et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories
Jan J. Cornelissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao et al.
NATURE MEDICINE (2007)
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
Francis Giles et al.
CLINICAL CANCER RESEARCH (2006)
Share Paper
